novel
human
coronaviru
cov
identifi
etiolog
agent
caus
sever
acut
respiratori
syndrom
sar
outbreak
spike
protein
viru
type
surfac
glycoprotein
mediat
bind
viru
host
receptor
subsequ
fusion
viral
host
membran
critic
role
viral
entri
protein
import
target
develop
antisar
cov
therapeut
prophylact
articl
review
structur
function
sar
cov
protein
context
role
viru
entri
topic
discuss
includ
interact
domain
sar
spike
protein
cellular
receptor
angiotensin
convert
enzym
structur
featur
ectodomain
antigen
determin
present
protein
natur
neutral
monoclon
antibodi
elicit
vivo
structur
heptad
repeat
domain
interact
form
sixhel
bundl
final
stage
fusion
opportun
design
develop
antisar
agent
base
inhibit
receptor
bind
therapeut
use
sdirect
monoclon
antibodi
inhibitor
complex
format
present
sever
acut
respiratori
syndrom
sar
atyp
pneumonia
initi
emerg
guangdong
provinc
southern
region
china
around
novemb
viru
subsequ
spread
rapidli
countri
around
world
within
short
period
time
infect
peopl
caus
death
time
outbreak
end
juli
mortal
rate
sar
approxim
compar
less
influenza
infect
show
mark
depend
age
unanticip
outbreak
caus
enorm
anxieti
uncertainti
public
health
manag
author
base
unknown
caus
pauciti
effect
therapeut
avail
sar
outbreak
ultim
contain
concert
effort
includ
patient
isol
intens
control
infect
hospit
tradit
quarantin
measur
issu
travel
advisori
enforc
world
health
organ
etiolog
agent
sar
quickli
identifi
coronaviru
cov
march
uniqu
global
collabor
effort
health
scientif
organ
phylogenet
analysi
amino
acid
sequenc
newli
discov
cov
reveal
distinct
previous
character
group
coronavirus
although
extens
genom
proteom
analys
suggest
distantli
relat
group
coronavirus
exampl
human
cov
murin
hepat
viru
mhv
like
coronavirus
sar
cov
envelop
positivestrand
rnaviru
contain
larg
genom
compris
base
constitut
open
read
frame
two
larg
overlap
open
read
frame
compris
approxim
twothird
genom
encod
singl
polyprotein
contain
replic
enzym
downstream
open
read
frame
encod
structur
protein
follow
order
spike
envelop
e
membran
nucleocapsid
n
four
structur
gene
eight
predict
open
read
frame
refer
accessori
gene
encod
nonstructur
protein
unknown
function
interferon
ribavirin
hiv
proteas
inhibitor
particularli
kaletra
combin
lopinavir
lowdos
ritonavir
use
empir
treat
sarsinfect
patient
affect
countri
outbreak
sar
cov
vaccin
offer
promis
effect
mean
prevent
control
potenti
futur
outbreak
remain
activ
develop
date
specif
efficaci
antivir
drug
readili
avail
prevent
treat
sar
although
widespread
sar
cov
infect
reemerg
follow
initi
outbreak
sporad
case
report
possibl
outbreak
emerg
natur
reservoir
remain
unpredict
consequ
effect
antivir
agent
sar
cov
desir
contrast
influenza
infect
viral
load
respiratori
tract
sar
co
vinfect
individu
peak
day
follow
onset
clinic
symptom
provid
wider
window
treatment
sar
cov
surfac
glycoprotein
design
spike
sprotein
respons
attach
entri
viru
host
cell
critic
earli
step
life
cycl
viru
repres
import
potenti
target
therapeut
intervent
similar
hiv
entri
sar
cov
host
cell
take
min
base
observ
view
electron
microscopi
infect
vero
cell
cultur
although
detail
kinet
studi
report
continu
tremend
interest
understand
precis
mechanist
step
associ
sar
cov
entri
sever
signific
find
report
within
short
period
time
articl
summar
develop
area
review
structur
function
sar
protein
antigen
determin
mechan
viral
entri
present
understood
highlight
opportun
therapeut
intervent
process
may
potenti
provid
treatment
sar
cov
infect
r
c
v
p
k
e
p
r
e
n
newli
discov
viru
distinct
three
known
group
cornonaviru
sar
cov
protein
share
amino
acid
ident
group
cornonavirus
figur
show
schemat
organ
sar
cov
protein
note
approxim
posit
variou
function
domain
identifi
date
ntermin
short
secretori
signal
sequenc
thought
cleav
cotransl
domain
globular
structur
respons
bind
host
cell
receptor
identifi
angiotensin
convert
enzym
section
sequenc
analysi
predict
protein
contain
heptad
repeat
region
type
found
sever
viral
fusion
protein
comput
sequenc
predict
togeth
systemat
amino
acid
map
studi
stalklik
domain
locat
region
amino
acid
region
extend
amino
acid
fig
biophys
analysi
show
isol
domain
highli
helic
assembl
thermal
stabl
coil
coil
wherea
domain
low
helic
content
less
stabl
element
associ
stabl
antiparallel
sixhelix
bundl
assembl
central
triplestrand
coil
coil
element
bound
section
intramolecular
interact
common
sever
virus
thought
mechan
viral
host
membran
brought
close
proxim
prelud
membran
fusion
consequ
sar
cov
protein
character
class
integr
membran
protein
share
membership
class
viral
envelop
glycoprotein
includ
protein
relat
group
cornonavirus
mhv
hiv
influenza
hemagglutinin
respiratori
syncyti
viru
rsv
f
protein
simian
parainfluenza
viru
f
protein
domain
sar
cov
conserv
domain
region
exhibit
higher
ident
cornonavirus
respect
interestingli
circular
dichroism
cd
analysi
proteinas
k
digest
studi
suggest
domain
bind
combin
helic
extend
conform
core
complex
structur
featur
resembl
mhv
subsequ
confirm
xray
crystallograph
studi
section
region
separ
amino
acid
interdomain
loop
similar
length
correspond
region
f
protein
rel
long
interdomain
loop
thought
counterbal
short
region
protein
proxim
viral
membran
provid
flexibl
requir
conform
chang
occur
membran
fusion
process
region
also
note
high
hydrophob
high
activ
membran
leakag
model
measur
activ
proteinderiv
synthet
peptid
ruptur
phospholipid
vesicl
encapsul
fluoresc
probe
molecul
suggest
import
role
facilit
fusion
process
type
surfac
glycoprotein
typic
process
proteolyt
individu
subunit
compris
membranebound
fusion
protein
receptorbind
subunit
associ
noncoval
agenc
disulfid
bond
hydrogenbond
interact
proteolyt
cleavag
usual
occur
proxim
fusion
peptid
unmask
expos
critic
mediat
fusion
process
howev
proteolyt
cleavag
sar
cov
protein
separ
domain
observ
consist
fact
contain
basic
amino
acid
cleavag
site
eg
rrxrr
found
group
cornonavirus
consequ
boundari
domain
precis
locat
predict
vicin
amino
acid
base
sequenc
analog
mhv
cleavag
protein
necessari
prerequisit
viral
entri
although
cleavag
protein
appear
enhanc
cellcel
fusion
observ
cell
express
sar
cov
protein
vero
cell
absenc
proteolyt
cleavag
protein
sar
covhost
membran
fusion
depend
activ
intern
fusion
peptid
predict
resid
amino
acid
region
rich
alanin
glycin
residu
locat
near
ntermin
howev
result
membran
partit
leakag
studi
use
proteinderiv
synthet
peptid
suggest
fusion
peptid
may
resid
toward
ctermin
start
amino
acid
possibl
proteolyt
process
protein
propos
base
detect
fragment
cell
lysat
sar
covinfect
vero
cell
monoclon
antibodi
howev
note
isol
correspond
fragment
report
small
stretch
approxim
amino
acid
rich
tyrosin
trytophan
residu
identifi
transmembran
anchor
highli
hydrophob
aromat
region
show
high
propens
partit
lipid
bilay
membran
leakag
model
system
region
togeth
interdomain
loop
mention
may
help
destabil
lipid
bilay
provid
addit
impetu
fusion
viral
host
membran
immedi
follow
transmembran
domain
short
cysteinerich
region
within
cytoplasm
domain
conserv
among
coronavirus
requir
fusion
activ
nativ
form
full
length
protein
exist
stabl
noncoval
complex
homotrim
ctermin
delet
studi
suggest
transmembran
andor
cytoplasm
domain
import
trimer
envelop
virus
express
surfac
glycoprotein
enter
host
cell
two
wellestablish
pathway
one
receptor
bindinginduc
conform
chang
viru
glycoprotein
lead
direct
fusion
viral
host
membran
cell
surfac
process
use
hivand
rsv
second
pathway
one
receptormedi
endocytosi
virion
taken
cell
endosom
compart
ph
endosom
fall
transit
lysozom
acid
environ
trigger
conform
chang
viru
glycoprotein
requir
membran
fusion
paradigm
use
promin
influenza
viru
whether
entri
sar
cov
ph
depend
phindepend
remain
establish
current
experiment
evid
definit
entri
sar
cov
proteinpseudotyp
viru
hiv
vector
vero
cell
cell
cell
inhibit
high
millimolar
concentr
nh
cl
suggest
phdepend
endocytot
process
howev
result
contradict
anoth
studi
use
lower
mm
concentr
nh
cl
observ
assay
fusion
cell
separ
express
sar
cov
protein
receptor
occur
effici
neutral
ph
moreov
entri
sar
cov
vero
cell
via
membran
fusion
cell
surfac
rather
endocytot
pathway
observ
electron
microscopi
also
note
cdanalysi
show
helic
peptid
amino
acid
increas
significantli
ph
compar
neutral
ph
suggest
low
ph
induc
signific
conform
chang
recent
studi
entri
ebola
viru
host
cell
process
mediat
disulfidelink
surfac
glycoprotein
use
pseudotyp
system
infect
vero
cell
reveal
third
process
trigger
viru
host
membran
fusion
ebola
viru
entri
process
appear
depend
initi
proteolyt
cleavag
endosom
cystein
proteas
capthepsin
b
l
follow
second
proteolyt
step
mediat
capthepsin
b
ph
studi
sar
cov
entri
describ
exclud
mechan
also
intrigu
note
detect
fragment
cell
lysat
sar
covinfect
vero
cell
report
recent
xray
crystallograph
structur
complex
repres
fusion
activ
form
protein
sar
cov
solv
resolut
structur
valid
conclus
drawn
earlier
biophys
studi
depict
figur
three
unit
amino
acid
associ
central
parallel
trimer
coil
coil
structur
three
element
amino
acid
bind
groov
complex
obliqu
antiparallel
direct
unit
consist
short
fiveturn
ahelix
amino
acid
contrast
longer
nineturn
helix
observ
element
hiv
rsv
f
protein
end
nand
cterminu
helix
peptid
chain
exist
extend
conform
reveal
anoth
structur
complex
pdb
extend
region
ntermin
span
five
addit
residu
complement
residu
coil
coil
interact
larg
hydrophob
helic
region
bind
deep
groov
complex
extend
region
bind
shallow
groov
extend
region
consolid
interact
sever
bsheetlik
hydrogen
bond
form
primari
amid
group
side
chain
asp
gln
main
chain
carbonyl
amid
nh
ntermin
residu
amino
acid
complex
shown
figur
extend
conform
residu
construct
use
crystallograph
studi
disord
suggest
region
connect
fusion
peptid
flexibl
allow
project
fusion
peptid
host
membran
use
strategi
similar
util
discoveri
inhibitor
hiv
fusion
ultim
produc
drug
enfuvirtid
peptid
deriv
heptad
repeat
domain
sar
cov
viru
evalu
capac
prevent
infect
vero
cell
cellbas
assay
ctermin
peptid
inhibitori
peptid
deriv
ntermin
result
consist
observ
relat
mhv
cov
area
peptid
amino
acid
show
inhibitori
activ
ec
mm
similarli
shorter
peptid
amino
acid
exhibit
ec
mm
sequenc
deriv
amino
acid
display
ec
mm
peptid
contain
key
region
defin
amino
acid
thought
inhibit
fusion
interf
format
fusionact
sixhelix
bundl
bind
prehairpin
state
inhibit
type
sequenc
specif
sinc
peptid
deriv
mhv
region
design
inact
sar
cov
fusion
howev
inhibitori
potenc
sar
cov
peptid
consider
lower
submicomolar
activ
measur
correspond
inhibit
mhv
fusion
peptid
exhibit
ec
mm
attribut
part
weaker
interact
within
sar
cov
sixhelix
bundl
indic
lower
thermal
stabil
compar
mhv
comparison
sar
cov
sixhelix
bundl
structur
mhv
reveal
structur
basi
weaker
interact
first
larger
void
volum
exist
insid
sar
cov
coil
coil
due
presenc
smaller
side
chain
leu
posit
instead
larger
side
chain
conserv
phe
posit
sar
cov
number
among
cornonavirus
second
sar
cov
shallow
hydrophob
pocket
interact
smaller
side
chain
residu
posit
compar
mhv
eg
ala
sar
cov
instead
val
mhv
third
buri
surfac
area
groov
interfac
sar
cov
less
mhv
complex
nevertheless
note
peptid
deriv
sar
cov
amino
acid
shown
ec
nm
infect
assay
use
vero
cell
peptid
almost
ident
one
shown
figur
potenc
suggest
peptid
repres
optim
interact
domain
anoth
contradictori
result
peptid
amino
acid
exhibit
inhibitori
activ
ec
mm
also
report
discrep
may
due
physicochem
properti
peptid
use
differ
assay
condit
includ
longer
incub
time
differ
readout
method
addit
peptidebas
inhibitor
small
molecul
inhibitor
identifi
use
assay
measur
bind
compound
protein
amino
acid
express
e
coli
tetraogalloylbdglucos
luteolin
found
inhibitor
bind
assay
micromolar
ec
shown
prevent
infect
vero
cell
pseudotyp
wildtyp
sar
cov
examin
sixhelix
bundl
crystal
structur
identifi
hydrophob
pocket
locat
potenti
target
design
small
molecul
inhibitor
pocket
occupi
side
chain
extend
conform
region
sixhelix
bundl
deeper
groov
helic
region
bind
could
also
consid
potenti
viabl
target
small
molecul
inhibitor
feasibl
approach
demonstr
recent
discoveri
small
molecul
target
similar
hydrophob
pocket
rsv
f
protein
potent
oral
bioavail
rsv
fusion
inhibitor
exhibit
antivir
efficaci
murin
model
rsv
infect
protein
identifi
host
receptor
sar
cov
recogn
protein
mediat
viru
bind
host
cell
subsequ
entri
interestingli
discov
recent
use
genomicbas
approach
character
enzym
homolog
ace
although
enzym
zinc
metalloproteas
function
carboxypeptidas
ace
peptidyl
dipeptidas
type
integr
membran
protein
cleav
one
amino
acid
ctermin
substrat
mainli
express
heart
kidney
test
like
ace
appear
import
enzym
reninangiotensin
cascad
ace
hydrolys
decapeptid
angiotensin
ai
vasoconstrictor
aii
act
conjunct
ace
convert
ai
heptapeptid
vasodil
establish
play
essenti
role
regul
cardiac
function
physiolog
function
enzym
remain
discov
recent
found
highli
express
lung
alveolar
epitheli
cell
enterocyt
small
intestin
locat
consist
pathogenesi
sar
cov
infect
although
sar
appear
mainli
respiratori
diseas
sar
cov
shown
infect
human
liver
cell
line
express
high
level
absenc
xray
crystal
structur
sar
cov
protein
bound
biochem
studi
use
discern
natur
interact
protein
process
identifi
sar
cov
receptor
bind
domain
receptor
clearli
demonstr
amino
acid
shown
critic
recognit
element
point
mutat
studi
indic
region
respons
key
interact
receptor
five
cy
residu
also
essenti
element
associ
solubl
form
domain
associ
dimer
bind
avidli
monom
dimer
domain
map
amino
acid
region
closer
amino
terminu
also
essenti
membran
fusion
peptidas
activ
shown
make
contribut
proteinmedi
entri
sar
cov
variant
activ
site
histidin
residu
modifi
asparagin
prove
equal
effect
receptor
viru
entri
wildtyp
moreov
truncat
cytoplasm
domain
amino
acid
affect
effici
sar
cov
infect
pseudotyp
assay
suggest
domain
essenti
entri
viru
solubl
form
conjug
human
fragment
shown
bind
high
affin
kd
nm
measur
surfac
plasmon
reson
biacor
methodolog
recent
crystallograph
structur
ectodomain
nativ
form
bound
activ
sitedirect
inhibitor
report
shown
figur
zinccontain
activ
site
locat
deep
insid
near
bottom
long
canyon
form
ntermin
subdomain
ctermin
subdomain
ii
notabl
structur
differ
nativ
inhibitorbound
form
inhibitorinduc
reposit
two
subdomain
rel
open
cleft
close
wrap
around
inhibitor
outer
edg
region
one
subdomian
move
much
crystal
structur
data
togeth
map
studi
identifi
locat
receptorbind
domain
cov
protein
provid
basi
molecular
model
bind
interact
two
protein
although
sequenc
similar
sar
cov
protein
protein
known
coronavirus
low
xray
structur
protein
yet
known
attempt
made
use
predict
secondari
structur
fold
recognit
approach
construct
model
sar
cov
protein
earli
model
studi
base
homolog
model
human
thread
model
known
receptorbind
domain
suggest
neg
charg
ridg
surround
catalyt
site
complementari
larg
posit
charg
surfac
receptorbind
domain
protein
inhibit
attach
sar
cov
protein
strategi
potenti
identifi
inhibitor
treatment
sar
infect
peptid
compris
amino
acid
protein
conjug
fc
domain
human
rbdfc
inhibit
proteinmedi
viral
entri
ec
nm
pseudotyp
assay
hybrid
peptid
potent
correspond
conjug
full
length
show
ec
nm
differ
activ
may
due
differ
physicochem
properti
exampl
solubl
possibl
receptorbind
domain
full
length
obscur
thu
less
access
solubl
form
shown
block
associ
domain
vero
cell
antibodi
inhibit
sar
cov
replic
vero
cell
ec
mgml
solubl
ectodomain
shown
inhibit
proteinmedi
viral
entri
pseudotyp
assay
catalyt
inact
form
conjug
fc
domain
human
potent
inhibit
sar
cov
infect
vero
cell
ec
nm
similar
receptorbas
approach
use
hiv
cellular
receptor
develop
antihiv
therapi
heteroconjug
complet
phase
ii
clinic
trail
sponsor
progen
human
monoclon
antibodi
phase
ii
clinic
studi
protein
potenti
target
therapeut
intervent
given
import
protein
cardiovascular
function
unknown
physiolog
role
potenti
mechanismbas
toxic
potent
select
small
molecul
inhibitor
discov
includ
fig
picomolar
inhibitor
fold
select
ace
hand
insensit
inhibit
captopril
relat
ace
inhibitor
larg
conform
chang
associ
outer
edg
two
subdomain
like
region
upon
bind
could
disrupt
interact
protein
henc
interfer
viral
entri
howev
hypothesi
remain
test
anoth
small
molecul
fig
identifi
use
phenotypebas
screen
vero
cell
infect
sar
cov
compound
subsequ
evalu
vero
cellbas
plaqu
reduct
assay
well
pseudotyp
viral
entri
assay
inhibit
viral
entri
plaqu
reduct
assay
micromolar
concentr
inhibit
either
sar
cov
proteas
helicas
howev
confirm
mode
action
await
select
resist
viru
resist
mutat
map
observ
sar
cov
infect
certain
cell
abundantli
express
also
infect
cell
devoid
express
suggest
receptor
coreceptor
requir
viral
entri
recent
ctype
lectin
type
ii
transmembran
glycoprotein
also
known
lsign
dcsignr
identifi
potenti
receptor
interact
amino
acid
domain
protein
sar
cov
howev
much
less
effici
promot
sar
cov
entri
importantli
protein
express
type
ii
alveolar
cell
endotheli
cell
human
lung
bind
homolog
dendrit
cellspecif
intracellular
adhes
molecul
nonintegrin
dcsign
also
observ
use
protein
pseudotyp
viru
dendrit
cell
promot
sar
cov
infect
transport
viru
target
cell
cell
suscept
infect
sar
cov
protein
contain
potenti
nlink
glycosyl
site
surfac
carbohydr
import
recognit
neutral
antibodi
antigen
determin
protein
elicit
potent
neutral
antibodi
found
locat
domain
peptid
fragment
repres
amino
acid
express
e
coli
system
synthet
peptid
compris
amino
acid
react
serum
sampl
convalesc
sar
patient
healthi
donor
peptid
domain
amino
acid
conjug
fc
domain
human
rbdfc
obtain
express
cell
transfect
correspond
plasmid
induc
potent
antibodi
respons
immun
rabbit
acebind
domaindirect
antibodi
inhibit
associ
neutral
infect
sar
covof
vero
cell
vitro
detail
studi
monoclon
antibodi
isol
mice
immun
rbdfc
found
recogn
differ
conformationallydefin
epitop
two
recogn
linear
epitop
within
receptorbind
domain
amino
acid
respect
interestingli
two
group
conformationdepend
antibodi
could
inhibit
rdbfc
bind
solubl
cell
antibodi
potent
neutral
sar
cov
pseudoviru
infect
cell
nanomolar
ec
two
antibodi
recogn
linear
epitop
exhibit
weak
neutral
properti
result
indic
antigen
heterogen
receptorbind
domain
contain
multipl
neutral
epitop
human
monoclon
antibodi
identifi
screen
antibodi
phage
display
librari
bind
girradi
whole
sar
cov
virion
neutral
infect
sar
cov
toward
vero
cell
nanomolar
potenc
level
neutral
correl
bind
affin
peptid
compris
amino
acid
protein
specif
bound
peptid
compris
amino
acid
nine
human
sar
cov
isol
sinc
approxim
reduct
bind
peptid
deriv
strain
possess
mutat
suggest
residu
import
bind
result
also
indic
import
evalu
antivir
spectrum
antisar
cov
monoclon
antibodi
human
nonimmun
recombin
monoclon
antibodi
neutral
sar
cov
infect
vero
cell
vitro
epitop
conform
depend
locat
amino
acid
protein
encompass
receptorbind
domain
result
consist
observ
competit
solubl
bind
domain
protein
record
k
nm
could
enhanc
nm
affin
compar
k
nativ
conjug
whole
human
variant
effect
neutral
sar
cov
infect
vero
cell
ec
nm
compar
ec
nm
mab
fulli
human
monoclon
antibodi
isol
transgen
mice
human
ig
gene
immun
recombin
ectodomain
protein
amino
acid
antibodi
neutral
infect
vero
cell
sar
cov
nm
concentr
mab
bound
full
length
protein
express
transfect
cell
bind
nm
solubl
fragment
protein
amino
acid
k
nm
measur
biacor
technolog
neutral
epitop
mab
map
amino
acid
cov
protein
within
receptorbind
domain
although
conformationallydefin
epitop
import
elicit
neutral
antibodi
mention
earlier
studi
use
denatur
protein
fragment
suggest
mab
may
recogn
linear
epitop
receptorbind
domain
protein
two
e
coliexpress
peptid
fragment
protein
amino
acid
recogn
mous
monoclon
antibodi
respect
subseg
studi
suggest
nine
amino
acid
sequenc
protein
may
constitut
minim
epitop
receptorbind
domain
signifi
inhibit
receptorbind
constitut
key
neutral
mechan
antisar
cov
vaccin
exampl
major
neutral
epitop
antibodi
elicit
mice
rabbit
monkey
immun
antisar
vaccin
adsmva
obtain
use
attenu
vaccinia
viru
ankara
express
full
length
sar
cov
protein
map
amino
acid
region
encompass
receptorbind
domain
antibodi
shown
bind
rbdfc
protein
administr
vaccin
monkey
provid
protect
sar
cov
challeng
detect
viru
shed
day
postchalleng
four
studi
anim
monoclon
antibodi
isol
mice
immun
inactiv
sar
cov
epitop
map
amino
acid
sequenc
protein
two
antibodi
show
much
higher
neutral
titer
sar
cov
infect
vero
cell
antibodi
recogn
region
domain
domain
vaccin
mice
dna
plasmid
encod
form
protein
includ
transmembran
domain
elicit
humor
cellular
immun
respons
howev
demonstr
neutral
antibodi
tcell
provid
immun
protect
pulmonari
viral
infect
murin
challeng
studi
use
sar
cov
experi
greater
log
reduct
viral
load
lung
observ
treat
mice
compar
control
anim
one
neutral
epitop
identifi
antibodi
rabbit
expos
dna
vaccin
map
amino
acid
domain
peptid
fragment
design
sii
compris
amino
acid
obtain
express
e
coli
sii
shown
bind
vero
cell
induc
monoclon
antibodi
mice
four
monoclon
antibodi
isol
recogn
monomer
trimer
nativ
form
sar
cov
protein
two
complet
inhibit
sar
cov
infect
vero
cell
concentr
mgml
interestingli
two
neutral
epitop
identifi
region
amino
acid
sii
peptid
locat
outsid
receptorbind
domain
amino
acid
sequenc
sar
cov
protein
identifi
one
epitop
recogn
antibodi
convalesc
sar
patient
domain
peptid
fragment
compris
amino
acid
elicit
antibodi
rabbit
mice
neutral
effect
toward
sarscov
pseudoviru
infect
cell
studi
also
suggest
epitop
ctermin
region
domain
suscept
antibodi
respons
neutral
epitop
emerg
dna
vaccineinduc
antibodi
gener
rabbit
map
amino
acid
also
outsid
region
antibodi
rais
rabbit
e
coliexpress
peptid
compris
amino
acid
residu
encompass
region
domain
specif
recogn
full
length
matur
protein
express
cell
surfac
shown
possess
strong
neutral
activ
sarscov
infect
vero
cell
sinc
antibodi
rais
rabbit
anoth
e
coliexpress
peptid
base
amino
acid
residu
possess
neutral
activ
toward
sarscov
pseudoviru
infect
cell
antibodi
elicit
peptid
fragment
amino
acid
also
neutral
sarscov
infect
epitop
like
locat
amino
acid
residu
region
addit
antibodi
epitop
tcell
epitop
also
locat
protein
transgen
mice
treat
adenoviru
vectorbas
sar
cov
pseudoviru
show
tcell
respons
found
induc
b
restrict
epitop
amino
acid
b
restrict
epitop
amino
acid
domain
amino
acid
sequenc
identifi
epitop
synthet
peptid
deriv
two
sequenc
induc
high
frequenc
ifngsecret
tcell
respons
pbmc
convalesc
sar
patient
nine
amino
acid
peptid
within
domain
amino
acid
rlnevaknl
elicitedspecif
hlaa
cytotox
lymphocyt
peripher
blood
lymphocyt
prepar
transgen
mice
identif
antigen
determin
protein
implic
vaccin
design
develop
includ
avoid
antibodyenhanc
viral
infect
inde
potenti
escal
viral
infect
sar
vaccin
current
major
clinic
concern
exampl
recent
immun
studi
conduct
ferret
candid
sar
cov
vaccin
base
vaccinia
viru
show
sign
worsen
liver
inflamm
induc
sar
cov
infect
strong
neutral
immun
respons
induc
peptid
fragment
receptorbind
domain
describ
also
point
subunit
vaccin
approach
antigen
determin
studi
present
also
suggest
monoclon
antibodi
target
protein
could
principl
provid
yet
anoth
effect
approach
inhibit
sar
cov
viral
entri
support
use
antisar
cov
monoclon
antibodi
addit
result
dna
vaccin
methodolog
discuss
come
experiment
result
mice
antibodi
alon
prevent
sar
cov
replic
lung
particularli
lower
respiratori
tract
result
correl
neutral
effect
observ
sar
cov
pseudotyp
assay
vitro
moreov
proteinspecif
neutral
monoclon
antibodi
isol
patient
recov
sar
infect
among
k
isotyp
shown
protect
sar
cov
replic
respiratori
tract
mous
model
encourag
result
came
three
anim
studi
mab
ferret
administ
mgkg
log
lower
viral
load
lung
better
lung
patholog
sar
cov
challeng
studi
administr
mgkg
mice
day
prior
sar
cov
challeng
produc
log
drop
viral
load
lower
respiratori
tract
compar
control
anim
wherea
use
mgkg
dose
reduc
viral
load
detect
limit
mab
protect
mice
infect
live
sar
cov
demonstr
greater
log
reduct
viral
load
lung
tissu
dose
mgkg
undetect
level
viru
observ
dose
mgkg
mab
consequ
clinic
trial
plan
mab
howev
studi
monoclon
antibodi
need
order
evalu
immunosafeti
antisar
cov
spectrum
efficaci
addit
anim
model
although
prophylact
efficaci
antisar
cov
monoclon
antibodi
anim
establish
futur
studi
also
requir
assess
safeti
therapeut
efficaci
treat
establish
infect
recent
report
use
pseudotyp
assay
reveal
escap
antibodi
neutral
sar
cov
viru
isol
patient
late
two
palm
civet
propos
natur
anim
reservoir
human
sar
cov
antibodi
use
compet
neutral
human
strain
identifi
earli
sar
outbreak
rais
caus
concern
interestingli
smediat
entri
pseudotyp
viru
deriv
late
exampl
less
sensit
inhibit
solubl
recombin
human
ectodomain
deriv
two
civet
enhanc
antibodi
interact
receptorbind
domain
antibodi
enhanc
viral
entri
howev
observ
human
strain
sar
cov
specif
studi
use
show
pseudotyp
sar
cov
deriv
complet
resist
neutral
result
mutat
residu
critic
bind
domain
implic
genet
mutat
protein
vaccin
develop
use
antibodi
therapeut
remain
determin
model
entri
sar
cov
host
cell
base
studi
report
date
envisag
upon
bind
domain
trimer
protein
host
cell
receptor
domain
carri
intern
fusion
peptid
expos
lead
insert
fusion
peptid
host
cell
membran
exist
receptor
coreceptor
requir
investig
conform
rearrang
domain
prehairpin
state
may
induc
interact
domain
receptor
whereupon
three
region
wrap
around
trimer
coil
coil
bring
viral
host
cell
membran
close
proxim
question
whether
endocytosi
viru
occur
whether
conform
chang
promot
low
ph
certain
unidentifi
proteas
endosom
still
need
resolv
howev
conceiv
multipl
entri
mechan
may
exploit
sar
cov
establish
infect
process
hairpin
format
protein
lipid
bilay
destabil
membran
mix
occur
along
hydrophob
pathway
guid
fusion
peptid
viral
membran
proxim
aromat
region
transmembran
anchor
result
format
fusion
pore
nucleocapsid
contain
viral
rna
enter
host
cell
sar
cov
entri
process
offer
sever
opportun
therapeut
intervent
includ
blockad
bind
protein
domain
receptor
inhibit
associ
hairpin
format
neutral
function
epitop
monoclon
antibodi
structur
inform
provid
crystallograph
structur
without
bound
inhibitor
sar
cov
core
complex
identif
antigen
determin
protein
offer
potenti
acceler
design
effect
therapeut
agent
certainli
crystallograph
structur
complex
well
proteinmonoclon
antibodi
complex
obtain
futur
provid
critic
insight
describ
inhibit
sar
coventri
process
feasibl
although
inhibitor
identifi
date
preliminari
natur
current
understand
sar
coventri
process
structur
inform
avail
emerg
inhibitor
togeth
form
solid
basi
futur
drug
discoveri
import
global
commun
adequ
prepar
anoth
sar
outbreak
thank
dr
andrew
good
help
prepar
figur
kapsun
yeung
born
mainland
china
grew
hong
kong
graduat
bsc
class
honor
chemistri
chines
univers
hong
kong
spend
year
work
research
assist
chemistri
depart
univers
hong
kong
obtain
croucher
foundat
scholarship
pursu
graduat
studi
cambridg
univers
uk
obtain
phd
synthet
organ
chemistri
follow
brief
postdoctor
research
period
chemistri
depart
scripp
research
institut
join
antivir
drug
discoveri
group
bristolmy
squibb
pharmaceut
research
institut
connecticut
current
senior
research
investig
design
synthes
potenti
drug
candid
treatment
hiv
hepat
c
viru
professor
carl
r
johnson
wayn
state
univers
devot
develop
new
synthet
methodolog
base
sulfur
chemistri
applic
total
synthesi
join
bristolmy
squibb
design
synthes
inhibitor
blood
platelet
aggreg
part
cardiovascular
therapeut
focu
contribut
identif
develop
neuroprotect
agent
largeconduct
ca
depend
potassium
channel
open
maxipost
tm
current
phase
clinic
trial
emerg
studi
sinc
respons
team
chemist
design
synthes
antivir
agent
direct
toward
develop
new
therapeut
option
treatment
hiv
hcv
rsv
influenza
